Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan
Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.12-04-2021
12-04-2021
Biocon Ltd - 532523 - Board to consider FY21 results & Final Dividend on April 28, 2021
Biocon Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on April 28, 2021, inter alia, to approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2021 and to consider the recommendation of final dividend, if any, amongst other routine matters.The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed April 01, 2021 to April 30, 2021 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.12-04-2021
BIOCON LTD. - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Trading Window Closure
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2021 ,inter alia, to consider and approve approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2021 and to consider the recommendation of final dividend, if any, amongst other routine matters.12-04-2021
BIOCON LTD. - 532523 - Compliance Certificate Under Regulation 40 (9) Of SEBI Listing Regulations For The Half Year Ended March 31, 2021.
With reference to the above subject, please find enclosed the Half Yearly Compliance Certificate under Regulation 40(9) of SEBI Listing Regulations, issued by Mr. Pradeep B Kulkarni, Practicing Company Secretary with regard to transfer/ sub-division/ consolidation/ renewal/ exchange or endorsement of calls/ allotment of monies for the half year ended March 31, 2021.12-04-2021
Biocon Pharma gets GMP compliance certificate from MHRA
Biocon Pharma Limited, a wholly-owned subsidiary of Biocon Limited, has received GMP compliance certificate from MHRA, UK.The company, in a regulatory12-04-2021
Biocon Ltd - 532523 - Biocon Pharma Limited, A Wholly Owned Subsidiary Of Biocon Limited, Receives GMP Compliance Certificate From MHRA, UK.
'This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru. The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection in the week of 22nd March, 2021, in the wake of travel restrictions amidst Covid-19.'12-04-2021
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to certify that the details of securities dematerialized and rematerialized during the quarter ended March 31, 2021, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed. The certificate from our RTA i.e. M/s. KFin Technologies Private Limited dated April 7, 2021, confirming the above, is enclosed for your reference.07-04-2021
BIOCON LTD. - 532523 - Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2021.
With reference to the above subject, we hereby confirm that activities in relation to both physical and electronic share transfer facilities were maintained during the period October 1, 2020 to March 31, 2021 (both days inclusive) by KFin Technologies Private Limited, Registrar and Share Transfer Agent ('RTA') of the Company, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000000221. A half yearly Compliance Certificate under Regulation 7(3) of the SEBI Listing Regulations, 2015 dated April 7, 2021 issued by KFin Technologies Private Limited affirming the same is enclosed herewith.07-04-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation01-04-2021
Biocon forms tie-up with Libbs Farmaceutica
Biotechnology major Biocon on Monday said its subsidiary has joined hands with Libbs Farmaceutica to launch generic drugs in Brazil.Biocon Pharma, a29-03-2021